Evidence map›Paper›PMID 31174616›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2019

Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results.

Lisa C Adams, Keno K Bressem, Phillipp Jurmeister, Ute L Fahlenkamp, Bernhard Ralla, Guenther Engel, Bernd Hamm, Jonas Busch, Marcus R Makowski

Abstract read
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Assessing the Impact of Imaging Parameters on MRI Measurement of Kidney TJournal of magnetic resonance imaging : JMRI · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. T1 and T2 mapping for identifying malignant lymph nodes in head and neck squamous cell carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lisa C AdamsDepartment of Radiology, Charité, Charitéplatz 1, 10117, Berlin, Germany. Lisa.adams@charite.de.ORCID http://orcid.org/0000-0001-5836-4542
Keno K BressemDepartment of Radiology, Charité, Hindenburgdamm 30, 12203, Berlin, Germany.
Phillipp JurmeisterDepartment of Pathology, Charité, Charitéplatz 1, 10117, Berlin, Germany.
Ute L FahlenkampDepartment of Radiology, Charité, Charitéplatz 1, 10117, Berlin, Germany.
Bernhard RallaDepartment of Urology, Charité, Charitéplatz 1, 10117, Berlin, Germany.
Guenther EngelDepartment of Radiology, Charité, Charitéplatz 1, 10117, Berlin, Germany.
Bernd HammDepartment of Radiology, Charité, Charitéplatz 1, 10117, Berlin, Germany.
Jonas BuschDepartment of Radiology, Charité, Charitéplatz 1, 10117, Berlin, Germany.
Marcus R MakowskiDepartment of Radiology, Charité, Charitéplatz 1, 10117, Berlin, Germany.

Funding

Berlin Institute of Health/ Charite Junior Clinician Scientist TrackBerlin Institute of Health/Charite Junior Clinican Scientist GrantBerlin Institute of Health/Charité BIH - Twinning Grant ProgramDeutsche Forschungsgemeinschaft SFB 1340/1 2018, 5943/31/41/91
6 · The paper itself

Abstract

backgroundCorrect staging and grading of patients with clear cell renal cell carcinoma (cRCC) is of clinical relevance for the prediction of operability and for individualized patient management. As partial or radial resection with postoperative tumor grading currently remain the methods of choice for the classification of cRCC, non-invasive preoperative alternatives to differentiate lower grade from higher grade cRCC would be beneficial.

methodsThis institutional-review-board approved cross-sectional study included twenty-seven patients (8 women, mean age ± SD, 61.3 ± 14.2) with histopathologically confirmed cRCC, graded according to the International Society of Urological Pathology (ISUP). A native, balanced steady-state free precession T2 mapping sequence (TrueFISP) was performed at 1.5 T. Quantitative T2 values were measured with circular 2D ROIs in the solid tumor portion and also in the normal renal parenchyma (cortex and medulla). To estimate the optimal cut-off T2 value for identifying lower grade cRCC, a Receiver Operating Characteristic Curve (ROC) analysis was performed and sensitivity and specificity were calculated. Students' t-tests were used to evaluate the differences in mean values for continuous variables, while intergroup differences were tested for significance with two-tailed Mann-Whitney-U tests.

resultsThere were significant differences between the T2 values for lower grade (ISUP 1-2) and higher grade (ISUP 3-4) cRCC (p < 0.001), with higher T2 values for lower grade cRCC compared to higher grade cRCC. The sensitivity and specificity for the differentiation of lower grade from higher grade tumors were 83.3% (95% CI: 0.59-0.96) and 88.9% (95% CI: 0.52-1.00), respectively, using a threshold value of ≥110 ms. Intraobserver/interobserver agreement for T2 measurements was excellent/substantial.

conclusionsNative T2 mapping based on a balanced steady-state free precession MR sequence might support an image-based distinction between lower and higher grade cRCC in a two-tier-system and could be a helpful addition to multiparametric imaging.

Indexed as

AgedCarcinoma, Renal CellFemaleHumansImage Interpretation, Computer-AssistedKidney NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedNeoplasm GradingSensitivity and SpecificityClear cell renal cell carcinomaMRI mapping techniquesQuantitative MRIT2 mappingTumor grading

Identifiers

PMID31174616
PMCPMC6555952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.